Inventor · disambiguated record
Kenji Murano
Also filed as: MURANO KENJI
9 granted patents·4 pending applications·132 citations·filing 1994–2014
86Inventor score
Files withFUJISAWA PHARMACEUTICAL CO6MIYATA TOSHIO2ASTELLAS PHARMA INC1RENASCIENCE CO LTD1TODA AYAKO1
Top patents by PatentIndex Score
13 records- 0188US7192943B2Cephem compoundsWAKUNAGA PHARMA CO LTD·Filed 2004·Granted Mar 20, 2007·24 cites·20 claims
- 0286US5670505APiperazine derivativesFUJISAWA PHARMACEUTICAL CO·Filed 1994·Granted Sep 23, 1997·62 cites·8 claims
- 0381US6884868B1Cyclic hexapeptides having antibiotic activityFUJISAWA PHARMACEUTICAL CO·Filed 2000·Granted Apr 26, 2005·20 cites·8 claims
- 0460US6232290B1Cyclic hexapeptides with antimicrobial activityFUJISAWA PHARMACEUTICAL CO·Filed 1999·Granted May 15, 2001·18 cites·9 claims
- 0557US5883098APiperazine derivativesFUJISAWA PHARMACEUTICAL CO·Filed 1997·Granted Mar 16, 1999·6 cites·4 claims
- 0648US2009012054A1Cephem Compounds and Use as Antimicrobial AgentsASTELLAS PHARMA INC·Filed 2007·Application pending·0 cites
- 0744US6884774B2Cyclic hexapeptide derivativesFUJISAWA PHARMACEUTICAL CO·Filed 2001·Granted Apr 26, 2005·0 cites·13 claims
- 0843US8415479B2Inhibitor of plasminogen activator inhibitor-1MIYATA TOSHIO·Filed 2009·Granted Apr 9, 2013·0 cites·17 claims
- 0942US2014296256A1Plasminogen activator inhibitor-1 inhibitorRENASCIENCE CO LTD·Filed 2014·Application pending·0 cites
- 1037US2005261177A1CompoundTODA AYAKO·Filed 2002·Application pending·0 cites
- 1136US8785473B2Plasminogen activator inhibitor-1 inhibitorMIYATA TOSHIO·Filed 2010·Granted Jul 22, 2014·0 cites·14 claims
- 1236US5939413APiperazine derivativesFUJISAWA PHARMACEUTICAL CO·Filed 1996·Granted Aug 17, 1999·2 cites·5 claims
- 1334US2004077667A1Quinazolinone derivativesFiled 2001·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Kenji Murano files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →